Wabitsch, S
Theyre suitable for those with type 2 diabetes requiring both glucose and weight management, patients with established cardiovascular disease benefiting from proven CV protection, and those who have achieved satisfactory results with GLP-1 therapy
About half the prescriptions for Ozempic, which is only approved to treat diabetes, went to people whose medical records do not indicate a diabetes diagnosis, Trilliant data shows
Antioxidant enzyme deficiencies, for dyslipidemic patients, were: 35% for sinus bradycardia and associated arrhythmias, 33% for sinus tachycardia, 33% for atrial fibrillation, 32% for atrial flutter and atrial extrasystolic arrhythmia, 30% for extrasystolic and ventricular arrhythmia, and 26% for paroxysmal supraventricular tachycardia
Even more impressive, over 85% of participants receiving the two highest retatrutide doses achieved complete resolution of steatosis, defined as liver fat content dropping below 5%